IBDEI0AQ ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14317,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/o Rem
 ;;^UTILITY(U,$J,358.3,14317,2)
 ;;=^336873
 ;;^UTILITY(U,$J,358.3,14318,0)
 ;;=208.81^^87^776^37
 ;;^UTILITY(U,$J,358.3,14318,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14318,1,1,0)
 ;;=1^208.81
 ;;^UTILITY(U,$J,358.3,14318,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type w/ Rem
 ;;^UTILITY(U,$J,358.3,14318,2)
 ;;=^267574
 ;;^UTILITY(U,$J,358.3,14319,0)
 ;;=208.82^^87^776^36
 ;;^UTILITY(U,$J,358.3,14319,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14319,1,1,0)
 ;;=1^208.82
 ;;^UTILITY(U,$J,358.3,14319,1,8,0)
 ;;=8^Oth Leuk Unspec Cell Type in Relap
 ;;^UTILITY(U,$J,358.3,14319,2)
 ;;=^336488
 ;;^UTILITY(U,$J,358.3,14320,0)
 ;;=209.00^^87^776^25
 ;;^UTILITY(U,$J,358.3,14320,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14320,1,1,0)
 ;;=1^209.00
 ;;^UTILITY(U,$J,358.3,14320,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Sm Intestine
 ;;^UTILITY(U,$J,358.3,14320,2)
 ;;=^336721
 ;;^UTILITY(U,$J,358.3,14321,0)
 ;;=209.01^^87^776^22
 ;;^UTILITY(U,$J,358.3,14321,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14321,1,1,0)
 ;;=1^209.01
 ;;^UTILITY(U,$J,358.3,14321,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Duodenum
 ;;^UTILITY(U,$J,358.3,14321,2)
 ;;=^336490
 ;;^UTILITY(U,$J,358.3,14322,0)
 ;;=209.02^^87^776^24
 ;;^UTILITY(U,$J,358.3,14322,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14322,1,1,0)
 ;;=1^209.02
 ;;^UTILITY(U,$J,358.3,14322,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Jejunum
 ;;^UTILITY(U,$J,358.3,14322,2)
 ;;=^336491
 ;;^UTILITY(U,$J,358.3,14323,0)
 ;;=209.03^^87^776^23
 ;;^UTILITY(U,$J,358.3,14323,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14323,1,1,0)
 ;;=1^209.03
 ;;^UTILITY(U,$J,358.3,14323,1,8,0)
 ;;=8^Mal Carcinoid Tumor,Ileum
 ;;^UTILITY(U,$J,358.3,14323,2)
 ;;=^336492
 ;;^UTILITY(U,$J,358.3,14324,0)
 ;;=204.00^^87^777^1
 ;;^UTILITY(U,$J,358.3,14324,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14324,1,1,0)
 ;;=1^204.00
 ;;^UTILITY(U,$J,358.3,14324,1,8,0)
 ;;=8^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,14324,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,14325,0)
 ;;=204.01^^87^777^3
 ;;^UTILITY(U,$J,358.3,14325,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14325,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,14325,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,14325,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,14326,0)
 ;;=204.10^^87^777^5
 ;;^UTILITY(U,$J,358.3,14326,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14326,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,14326,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,14326,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,14327,0)
 ;;=204.11^^87^777^7
 ;;^UTILITY(U,$J,358.3,14327,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14327,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,14327,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,14327,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,14328,0)
 ;;=201.90^^87^777^11
 ;;^UTILITY(U,$J,358.3,14328,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14328,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,14328,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,14328,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,14329,0)
 ;;=202.00^^87^777^19
 ;;^UTILITY(U,$J,358.3,14329,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14329,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,14329,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,14329,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,14330,0)
 ;;=200.20^^87^777^16
 ;;^UTILITY(U,$J,358.3,14330,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14330,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,14330,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,14330,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,14331,0)
 ;;=202.10^^87^777^29
 ;;^UTILITY(U,$J,358.3,14331,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14331,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,14331,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,14331,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,14332,0)
 ;;=273.3^^87^777^21
 ;;^UTILITY(U,$J,358.3,14332,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14332,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,14332,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,14332,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,14333,0)
 ;;=203.00^^87^777^28
 ;;^UTILITY(U,$J,358.3,14333,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14333,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,14333,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,14333,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,14334,0)
 ;;=203.01^^87^777^27
 ;;^UTILITY(U,$J,358.3,14334,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14334,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,14334,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,14334,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,14335,0)
 ;;=202.40^^87^777^8
 ;;^UTILITY(U,$J,358.3,14335,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14335,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,14335,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,14335,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,14336,0)
 ;;=200.10^^87^777^18
 ;;^UTILITY(U,$J,358.3,14336,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14336,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,14336,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,14336,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,14337,0)
 ;;=273.1^^87^777^25
 ;;^UTILITY(U,$J,358.3,14337,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14337,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,14337,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,14337,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,14338,0)
 ;;=238.79^^87^777^20
 ;;^UTILITY(U,$J,358.3,14338,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14338,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,14338,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,14338,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,14339,0)
 ;;=202.90^^87^777^17
 ;;^UTILITY(U,$J,358.3,14339,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14339,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,14339,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,14339,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,14340,0)
 ;;=200.30^^87^777^23
 ;;^UTILITY(U,$J,358.3,14340,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14340,1,1,0)
 ;;=1^200.30
 ;;^UTILITY(U,$J,358.3,14340,1,8,0)
 ;;=8^Marginal Zone Lymphoma
 ;;^UTILITY(U,$J,358.3,14340,2)
 ;;=^335296
 ;;^UTILITY(U,$J,358.3,14341,0)
 ;;=200.40^^87^777^22
 ;;^UTILITY(U,$J,358.3,14341,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14341,1,1,0)
 ;;=1^200.40
 ;;^UTILITY(U,$J,358.3,14341,1,8,0)
 ;;=8^Mantle Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,14341,2)
 ;;=^335297
 ;;^UTILITY(U,$J,358.3,14342,0)
 ;;=200.50^^87^777^32
 ;;^UTILITY(U,$J,358.3,14342,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14342,1,1,0)
 ;;=1^200.50
 ;;^UTILITY(U,$J,358.3,14342,1,8,0)
 ;;=8^Prim CNS Lymphoma
 ;;^UTILITY(U,$J,358.3,14342,2)
 ;;=^335298
 ;;^UTILITY(U,$J,358.3,14343,0)
 ;;=200.60^^87^777^4
 ;;^UTILITY(U,$J,358.3,14343,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14343,1,1,0)
 ;;=1^200.60
 ;;^UTILITY(U,$J,358.3,14343,1,8,0)
 ;;=8^Anaplastic Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,14343,2)
 ;;=^335299
 ;;^UTILITY(U,$J,358.3,14344,0)
 ;;=200.70^^87^777^13
 ;;^UTILITY(U,$J,358.3,14344,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14344,1,1,0)
 ;;=1^200.70
 ;;^UTILITY(U,$J,358.3,14344,1,8,0)
 ;;=8^Large Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,14344,2)
 ;;=^335300
 ;;^UTILITY(U,$J,358.3,14345,0)
 ;;=200.80^^87^777^31
 ;;^UTILITY(U,$J,358.3,14345,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14345,1,1,0)
 ;;=1^200.80
 ;;^UTILITY(U,$J,358.3,14345,1,8,0)
 ;;=8^Oth Named Variants
 ;;^UTILITY(U,$J,358.3,14345,2)
 ;;=^176827
 ;;^UTILITY(U,$J,358.3,14346,0)
 ;;=201.00^^87^777^9
 ;;^UTILITY(U,$J,358.3,14346,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14346,1,1,0)
 ;;=1^201.00
 ;;^UTILITY(U,$J,358.3,14346,1,8,0)
 ;;=8^Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,14346,2)
 ;;=^265557
 ;;^UTILITY(U,$J,358.3,14347,0)
 ;;=201.10^^87^777^10
 ;;^UTILITY(U,$J,358.3,14347,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14347,1,1,0)
 ;;=1^201.10
 ;;^UTILITY(U,$J,358.3,14347,1,8,0)
 ;;=8^Hodgkin's Granuloma
 ;;^UTILITY(U,$J,358.3,14347,2)
 ;;=^58273
 ;;^UTILITY(U,$J,358.3,14348,0)
 ;;=201.20^^87^777^12
 ;;^UTILITY(U,$J,358.3,14348,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14348,1,1,0)
 ;;=1^201.20
 ;;^UTILITY(U,$J,358.3,14348,1,8,0)
 ;;=8^Hodgkin's Sarcoma
 ;;^UTILITY(U,$J,358.3,14348,2)
 ;;=^265560
 ;;^UTILITY(U,$J,358.3,14349,0)
 ;;=201.40^^87^777^15
 ;;^UTILITY(U,$J,358.3,14349,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14349,1,1,0)
 ;;=1^201.40
 ;;^UTILITY(U,$J,358.3,14349,1,8,0)
 ;;=8^Lymphocytic-Histiocytic
 ;;^UTILITY(U,$J,358.3,14349,2)
 ;;=^265549
 ;;^UTILITY(U,$J,358.3,14350,0)
 ;;=201.50^^87^777^30
 ;;^UTILITY(U,$J,358.3,14350,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14350,1,1,0)
 ;;=1^201.50
 ;;^UTILITY(U,$J,358.3,14350,1,8,0)
 ;;=8^Nodular Sclerosis
 ;;^UTILITY(U,$J,358.3,14350,2)
 ;;=^265555
 ;;^UTILITY(U,$J,358.3,14351,0)
 ;;=201.60^^87^777^24
 ;;^UTILITY(U,$J,358.3,14351,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14351,1,1,0)
 ;;=1^201.60
 ;;^UTILITY(U,$J,358.3,14351,1,8,0)
 ;;=8^Mixed Cellularity
 ;;^UTILITY(U,$J,358.3,14351,2)
 ;;=^265551
 ;;^UTILITY(U,$J,358.3,14352,0)
 ;;=201.70^^87^777^14
 ;;^UTILITY(U,$J,358.3,14352,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14352,1,1,0)
 ;;=1^201.70
 ;;^UTILITY(U,$J,358.3,14352,1,8,0)
 ;;=8^Lymphocytic Depletion
 ;;^UTILITY(U,$J,358.3,14352,2)
 ;;=^265553
 ;;^UTILITY(U,$J,358.3,14353,0)
 ;;=203.02^^87^777^26
 ;;^UTILITY(U,$J,358.3,14353,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14353,1,1,0)
 ;;=1^203.02
 ;;^UTILITY(U,$J,358.3,14353,1,8,0)
 ;;=8^Multiple Myeloma in Relapse
 ;;^UTILITY(U,$J,358.3,14353,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,14354,0)
 ;;=204.02^^87^777^2
 ;;^UTILITY(U,$J,358.3,14354,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14354,1,1,0)
 ;;=1^204.02
 ;;^UTILITY(U,$J,358.3,14354,1,8,0)
 ;;=8^ALL,in Relapse
